> |
Abbreviated instructions for reconstitution, dosage,
and administration |
> |
One 50 mg vial of sterile, lyophilized TNKase powder |
> |
Sterile, graduated, disposable B-D® 10 mL syringe with TwinPak™ Dual Cannula Device |
> |
10 mL vial of Sterile Water for Injection, USP |
> |
TNKase full prescribing information |
> |
3 alcohol prep pads |
Wastage Replacement Program: For information about our wastage replacement program, please contact your local Genentech representative or call Genentech Customer Service at 1-800-551-2231.
Indication: For use in mortality reduction associated with acute myocardial infarction (AMI). Treatment should be initiated as soon as possible after the onset of AMI symptoms.
Safety Information: TNKase therapy is contraindicated in the following conditions due to an increased risk of bleeding: active internal bleeding, history of cerebrovascular accident, intracranial or intraspinal surgery or trauma within 2 months, intracranial neoplasm, arteriovenous malformation, or aneurysm, known bleeding diathesis, and severe uncontrolled hypertension.
All thrombolytic agents increase the risk of bleeding, including intracranial bleeding, and should be used only in eligible patients. In addition, thrombolytic therapy increases the risk of stroke, including hemorrhagic stroke, particularly in elderly patients. In patients with large ST segment elevation myocardial infarction, physicians should choose either thrombolysis or percutaneous coronary intervention (PCI) as the primary treatment strategy for reperfusion. Rescue PCI or subsequent elective PCI may be performed after administration of thrombolytic therapies if medically appropriate.
|
